Original Article
Combining ECMO with IABP for the Treatment of Critically Ill Adult Heart Failure Patients

https://doi.org/10.1016/j.hlc.2013.10.081Get rights and content

Objective

To discuss the experience of combining extra-corporeal membrane oxygenation (ECMO) with intra-aortic balloon pump (IABP) for the treatment of acute heart failure in critically ill adults.

Methods

The clinical data of 54 patients who received ECMO combined with IABP due to acute heart failure between January 2008 and July 2012 were retrospectively analysed. Thirty-eight of the patients were male, and 16 were female; the mean age was 57 ± 11. Thirty-nine of the patients received IABP first but were still unable to maintain adequate circulation, and were then given ECMO; the other 15 underwent ECMO first, but due to increased left ventricular load, the opening of the aortic valve was restricted and IABP was then introduced.

Results

Thirty-four patients (63%) were successfully weaned from ECMO; 21 patients (38.9%) survived to discharge. Major complications that occurred were renal failure (27 cases), infection (20 cases), blood plasma leakage in the oxygenator (13 cases), bleeding (18 cases), limb ischaemia (eight cases), and neurological complications (seven cases); in the group of patients who did not survive, the rates of bleeding occurrence, infection and renal failure were markedly higher than in the survived patients group. In both groups, the longer the patients were on support, the more improvement they showed in terms of MAP, CVP, Lac, SvO2 and IS.

Conclusion

ECMO and IABP may have synergistic effects and play complementary roles in the treatment of acute cardiac failure; with timely administration, active prevention and treatment of complications, they can improve treatment outcome.

Introduction

The IABP is a device which increases aortic root pressure during diastole by enhancing blood flow into the coronary arteries, thus increasing blood supply to the cardiac muscle; meanwhile, it decreases the pressure in the aorta during systole, reducing left ventricular afterload and thus reducing cardiac muscle oxygen consumption. These effects allow the weakened heart to recover its function. IABP can improve blood flow to internal organs to a certain extent, while increasing cardiac output by 10–20% [1], thus providing indispensable assistance in meeting the body's metabolic needs. IABP is currently the most commonly used mechanical circulatory support device in the treatment of acute heart failure; when administered in a timely manner, it can play a critical role in the rescue of patients with acute ischaemic myocardial infarctions [2], [3]. Despite this, IABP cannot replace the physiological pumping of the heart; for patients whose cardiac muscle is already severely damaged, IABP support may not raise cardiac output sufficiently to meet the body's needs, creating the necessity for further circulatory support.

The working principle of ECMO is to draw a portion of the body's blood outside of the body, oxygenate it, and then return it to the circulation; this improves oxygen supply throughout the body, providing some compensation for the reduction in cardiac output caused by impaired heart function and improving blood flow to tissues and organs. Furthermore, the veno-arterial type of ECMO can reduce cardiac preload by diverting blood flow, reducing cardiac oxygen demand even more; therefore ECMO can be used to treat acute heart failure. ECMO can also be used to treat acute lung failure; for example, when ECMO is applied to treatment of patients with acute respiratory distress syndrome (ARDS), it can effectively increase blood oxygen content and ensure sufficient oxygen transport [4]. However, for the venous-femoral arterial modality, when ECMO flow is increased, there is a corresponding increase in left ventricular afterload, which, when severe, can restrict the opening of the aortic valve, affecting left ventricular ejection and possibly lead to thrombus formation in the left ventricle [5], [6]. In the venous-ascending aortic modality, on the other hand, continuous non-pulsating blood flow may reduce aortic root pressure during diastole, affecting blood supply to the cardiac muscle.

Due to the limitations of both methods, neither IABP nor ECMO alone can achieve ideal outcomes in patients with severe disease [7], while combining them can in principle have a synergistic and complementary effect. The goal of this article is to discuss the clinical experience of combining ECMO with IABP for the treatment of acute heart failure in adults.

Section snippets

Patients

In the period from January 2008 to July 2012, a total of 54 adult patients with acute heart failure received combined ECMO and IABP support at our hospital. Thirty-eight were male, 16 were female, and the mean age was 57 ± 11 (with a range of 24–75). The basic demographics of all patients are shown in Table 1. The surgical operations they received are shown in Table 2. In our study 39 patients received IABP first but could not maintain adequate circulation, and were then treated with ECMO; 15

Results

  • 1.

    Survival Rates and Prognosis

Thirty-four patients (63%) were successfully weaned from mechanical life support (weaned group); of these patients, 13 (24%) died from various complications after weaning, while 21 (39%) survived to discharge. Twenty patients (37%) were not weaned from mechanical circulatory support (un-weaned group); 14 of these patients (26%) died due to inability of the heart to recover its function, while six (11%) were taken off support when family members decided to forego

Discussion

There were 54 patients initially included in this study and all of them showed improvements in terms of overall circulation in addition to vasoactive drug applications; the rate of effectiveness was 100%. Thirty-four of the patients were successfully weaned from mechanical circulatory support, and 21 patients survived to discharge (39% of the total patient number). This shows that a combination of ECMO and IABP can be used to treat patients with serious symptoms after heart surgery and there is

Conflict of Interest

No conflicts of interest declared.

Acknowledgements

We specially thank Professor Ming Jia from the Capital Medical University affiliated Beijing Anzhen Hospital for his support.

References (16)

There are more references available in the full text version of this article.

Cited by (0)

1

These authors contributed equally to this work.

View full text